TY - JOUR
T1 - Survival and years of life lost in different age cohorts of patients with multiple myeloma
AU - Ludwig, Heinz
AU - Bolejack, Vanessa
AU - Crowley, John
AU - Bladé, Joan
AU - San Miguel, Jesus
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
AU - Shimizu, Kazuyuki
AU - Turesson, Ingemar
AU - Westin, Jan
AU - Sonneveld, Pieter
AU - Cavo, Michele
AU - Boccadoro, Mario
AU - Palumbo, Antonio
AU - Tosi, Patrizia
AU - Harousseau, Jean Luc
AU - Attal, Michel
AU - Barlogie, Bart
AU - Stewart, A. Keith
AU - Durie, Brian
PY - 2010/3/20
Y1 - 2010/3/20
N2 - Purpose: To assess the impact of age on outcome and to analyze the projected years of life lost in patients with multiple myeloma. Patients and Methods: Ten thousand five hundred forty-nine patients were evaluated; 6,996 patients were treated with conventional chemotherapy, and 3,553 patients were treated with high-dose therapy with autologous stem-cell transplantation. Results: Mean observed and relative overall survival times in the entire cohort were 3.7 and 3.9 years, respectively. Observed survival decreased steadily from 6.4 years in patients younger than age 50 years to 2.5 years in patients ≥ age 80 years. A similar decrease was noted for relative survival. Higher age correlated significantly with higher International Staging System (ISS) stage. Relative excess risk of death differed significantly between 10-year age cohorts beginning from age 40 years (P < .001 for age 50 to 59 v age 40 to 49, P < .001 for age 60 to 69 v age 50 to 59, P < .001 for age 70 to 79 v age 60 to 69, and P = .009 for age ≥ 80 v 70 to 79). The average years of life lost per patient was 16.8 years in the entire patient cohort and decreased steadily from 36.1 years in patients younger than 40 years old to 4.6 years in patients ≥ age 80 years. Conclusion: Age is associated with higher ISS stage and is an important risk factor for early mortality. Survival declined continuously by each decade from age 50 to age ≥ 80 from more than 6 to less than 3 years. The average of years of life lost in patients with myeloma is higher than in many other cancers and amounts to more than 30 years in patients younger than 40 years old but decreases to less than 5 years in patients age 80 years or older.
AB - Purpose: To assess the impact of age on outcome and to analyze the projected years of life lost in patients with multiple myeloma. Patients and Methods: Ten thousand five hundred forty-nine patients were evaluated; 6,996 patients were treated with conventional chemotherapy, and 3,553 patients were treated with high-dose therapy with autologous stem-cell transplantation. Results: Mean observed and relative overall survival times in the entire cohort were 3.7 and 3.9 years, respectively. Observed survival decreased steadily from 6.4 years in patients younger than age 50 years to 2.5 years in patients ≥ age 80 years. A similar decrease was noted for relative survival. Higher age correlated significantly with higher International Staging System (ISS) stage. Relative excess risk of death differed significantly between 10-year age cohorts beginning from age 40 years (P < .001 for age 50 to 59 v age 40 to 49, P < .001 for age 60 to 69 v age 50 to 59, P < .001 for age 70 to 79 v age 60 to 69, and P = .009 for age ≥ 80 v 70 to 79). The average years of life lost per patient was 16.8 years in the entire patient cohort and decreased steadily from 36.1 years in patients younger than 40 years old to 4.6 years in patients ≥ age 80 years. Conclusion: Age is associated with higher ISS stage and is an important risk factor for early mortality. Survival declined continuously by each decade from age 50 to age ≥ 80 from more than 6 to less than 3 years. The average of years of life lost in patients with myeloma is higher than in many other cancers and amounts to more than 30 years in patients younger than 40 years old but decreases to less than 5 years in patients age 80 years or older.
UR - http://www.scopus.com/inward/record.url?scp=77951923656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951923656&partnerID=8YFLogxK
U2 - 10.1200/JCO.2009.25.2114
DO - 10.1200/JCO.2009.25.2114
M3 - Article
C2 - 20177027
AN - SCOPUS:77951923656
SN - 0732-183X
VL - 28
SP - 1599
EP - 1605
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 9
ER -